Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by bball67on Sep 24, 2021 11:17am
110 Views
Post# 33913906

RE:RE:RE:RE:RE:RE:fidelity?

RE:RE:RE:RE:RE:RE:fidelity?David, here is some information to help you understand. Promis issued 196M shares and raised $28M in last four months. Total shares are now approximately 432M. That is a 46% dilution with new owners. I said the Boston Group owns 20-25% of the Company-I think my number is probably low. Have you thoroughly checked out the backgrounds and bios of the four Boston investors and their connection to Alzheimers? Todays market capitalization is approximately US $63M, 10X is $630M market cap and 20X is $1.26 billion. More is 1.5 billion or 2.0 billion. Do you think this is possible or laughable? As for me, I am well over 1.2M shares and have placed a big bet on the outcome and the developments to come in the next six months.
<< Previous
Bullboard Posts
Next >>